{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:20:30Z","timestamp":1790911230113,"version":"4.1.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T00:00:00Z","timestamp":1696291200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["836031008"],"award-info":[{"award-number":["836031008"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ekir.2023.10.003","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T22:09:35Z","timestamp":1697148575000},"page":"145-151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Ex\u00a0Vivo Test of Complement Dysregulation in Atypical Hemolytic Uremic Syndrome Kidney Transplant patients: A Pilot Study"],"prefix":"10.1016","volume":"9","author":[{"given":"Caroline","family":"Duineveld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romy N.","family":"Bouwmeester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambertus P.W.J.","family":"van den Heuvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole C.A.J.","family":"van de Kar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack F.M.","family":"Wetzels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2023.10.003_bib1","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.seminhematol.2018.04.009","article-title":"Anticomplement treatment in atypical and typical hemolytic uremic syndrome","volume":"55","author":"Fakhouri","year":"2018","journal-title":"Semin Hematol"},{"key":"10.1016\/j.ekir.2023.10.003_bib2","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/ajt.12077","article-title":"Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome","volume":"13","author":"Le Quintrec","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2023.10.003_bib3","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2023.10.003_bib4","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ekir.2023.01.016","article-title":"Eculizumab rescue therapy in patients with recurrent atypical hemolytic uremic syndrome after kidney transplantation","volume":"8","author":"Duineveld","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2023.10.003_bib5","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1681\/ASN.2019040331","article-title":"Use of highly individualized complement blockade has revolutionized clinical outcomes after kidney transplantation and renal epidemiology of atypical hemolytic uremic syndrome","volume":"30","author":"Zuber","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.10.003_bib6","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1111\/j.1600-6143.2012.04252.x","article-title":"Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation","volume":"12","author":"Zuber","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2023.10.003_bib7","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00467-010-1708-6","article-title":"Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation","volume":"26","author":"Al-Akash","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2023.10.003_bib8","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.transproceed.2015.08.004","article-title":"Thrombotic microangiopathy as a cause of chronic kidney transplant dysfunction: case report demonstrating successful treatment with eculizumab","volume":"47","author":"Iqbal","year":"2015","journal-title":"Transplant Proc"},{"issue":"suppl 1","key":"10.1016\/j.ekir.2023.10.003_bib9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/nep.12937","article-title":"Absence of thrombocytopaenia and\/or microangiopathic haemolytic anaemia does not reliably exclude recurrence of atypical haemolytic uraemic syndrome after kidney transplantation","volume":"22","author":"Krishnan","year":"2017","journal-title":"Nephrol (Carlton)"},{"key":"10.1016\/j.ekir.2023.10.003_bib10","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00467-004-1565-2","article-title":"Atypical relapse of hemolytic uremic syndrome after transplantation","volume":"19","author":"Olie","year":"2004","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2023.10.003_bib11","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.trre.2017.10.001","article-title":"De novo thrombotic microangiopathy after kidney transplantation","volume":"32","author":"Garg","year":"2018","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1016\/j.ekir.2023.10.003_bib12","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","article-title":"Dynamics of complement activation in aHUS and how to monitor eculizumab therapy","volume":"124","author":"Noris","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2023.10.003_bib13","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/j.ajkd.2018.11.012","article-title":"An ex\u00a0vivo test of complement activation on endothelium for individualized eculizumab therapy in hemolytic uremic syndrome","volume":"74","author":"Galbusera","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2023.10.003_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1112257","article-title":"An ex\u00a0vivo test to investigate genetic factors conferring susceptibility to atypical haemolytic uremic syndrome","volume":"14","author":"Gastoldi","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2023.10.003_bib16","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41581-021-00424-4","article-title":"Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics","volume":"17","author":"Fakhouri","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2023.10.003_bib17","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.ekir.2021.01.034","article-title":"Functional and genetic landscape of complement dysregulation along the spectrum of thrombotic microangiopathy and its potential implications on clinical outcomes","volume":"6","author":"Timmermans","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2023.10.003_bib18","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1681\/ASN.0000000000000182","article-title":"Efficacy and safety of eculizumab in pediatric patients affected by Shiga toxin-related hemolytic and uremic syndrome: a randomized, placebo-controlled trial","volume":"34","author":"Garnier","year":"2023","journal-title":"J\u00a0Am Soc Nephrol"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024923015322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024923015322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T03:45:40Z","timestamp":1762832740000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024923015322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S2468024923015322"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2023.10.003","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ex\u00a0Vivo Test of Complement Dysregulation in Atypical Hemolytic Uremic Syndrome Kidney Transplant patients: A Pilot Study","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2023.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}